<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210728052003N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-09-08</date_registration>
      <primary_sponsor>Sanandaj University of Medical Sciences</primary_sponsor>
      <public_title>A comparison between ketamine and precedex in treatment of shivering</public_title>
      <acronym></acronym>
      <scientific_title>A comparison between intravenous ketamine and precedex (dexmedetomidine) in treatment of postoperative shivering after nose surgeries</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-03-20</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>88</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/57767</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: ASA classification:1: A person with normal health without any systemic problems. 2: A person with mild systemic disease who has not had functional limitations. 3: A person with severe systemic disease who has functional limitations for the person. 4: A person who has a severe systemic disease and whose life is in danger. 5: A person who is dying and is not expected to survive surgery. 6: A person who has died of brain damage and is sent to the operating room to donate an organ; Both groups of patients are anesthetized in a similar way:Premedication:Fentanyl 1.5 µg / kg / IV, Midazolam 1mg / IV, Lidocaine 1mg / kg / IV, Dexamethasone 8 mg / IV. All patients receive the fluid they need to compensate for the NPO based on the anesthesia group policies. Induction of anesthesia: Propofol 1.5mg / kg / IV then Atracurium 0.5mg / kg / IV. Maintenance: Isoflurane 1.5% + N2O (3L) + O2 (3L).Reverse neuromuscular block at the end of surgery: Atropine 1.5 mg and Neostigmine 2.5 mg. All patients are tubed with a spiral tube and receive the fluid they need during the operation according to the policies of the anesthesia group. The operating room temperature in all patients is 27 degrees Celsius. Cover all patients during surgery and in Recovery is the same and blankets are used to warm them in recovery. For both groups of patients, gender, age, weight, height, duration of anesthesia and duration of surgery are recorded. Gender based on men and women; Age by year; Weight by scales; Height by meter; Duration of anesthesia in minutes; Duration of surgery in minutes, Randomization description: Patients are divided into two groups receiving ketamine and Precedex using the formation of 4 random blocks and random selection from these blocks, Blinding description: To blind the study, the drugs are diluted in a volume of 2 ml and injected with syringes encrypted by a doctor who does not know the details of the treatment of patients. Patients are also not informed about the type of drug received.</study_design>
      <phase>4</phase>
      <hc_freetext>postoperative shivering.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Ketamine group: They receives 0.3 mg / kg / IV treatment of ketamine. Intervention 2: Intervention group: Percedex receiving group: They receive 1 µg / kg / IV treatment of Percedex.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data including proposal, raw data and project reports

When:
Data is available from the legal system six months after publication for two years.

To whom:
All persons will access to the data upon request to the Research and Technology Dept. of Kurdistan Medical Science.

Conditions:
For legal issues and the need to use data in future studies

Where to obtain:
Sepideh Salehi
Address: Sanandaj University of Medical Sciences, Pasdaran Blvd., Sanandaj, Kurdistan Province
Postal code:6617713446
00989142567880
sepideh.salehi.9595@gmail.com
Behzad Ahsan
Address: Kowsar Hospital, Mahvi Blvd., Pasdaran Blvd., Sanandaj, Kurdistan Province
Postal code:6617983476
00989181719003
behzad.ahsan@muk.ac.ir

How to obtain:
After submitting a request to the Research and Technology Dept. of Kurdistan Medical Science , a call for submission is given.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Behzad Ahsan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kowsar Hospital, Mahvi Blvd., Pasdaran Blvd., Sanandaj, Kurdistan Province</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617983476</zip>
        <telephone>+98 87 3361 1232</telephone>
        <email>behzad.ahsan@muk.ac.ir</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Behzad Ahsan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Kowsar Hospital, Mahvi Blvd., Pasdaran Blvd., Sanandaj, Kurdistan Province</address>
        <city>Sanandaj</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>6617983476</zip>
        <telephone>+98 87 3361 1232</telephone>
        <email>behzad.ahsan@muk.ac.ir</email>
        <affiliation>Sanandaj University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients undergoing elective nasal surgery with a duration of 1-2 hours (including rhinoplasty, septoplasty, functional endoscopic sinus surgery, polyps, and other intranasal masses)
Patients receiving general anesthesia
Patients with shivering after surgery
Patients with ASA class one and two</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Patients with ASA class three and more
Patients with a history of tremor and Parkinson's disease
Patients with a history of thyroid, heart, kidney, and liver diseases, anemia (hemoglobin less than 9)
Patients with a history of allergies
Patients receiving blood during surgery
Patients with a history of neurology and psychology diseases
Patients with a history of myopathy
Drug users</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M61.50</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other ossification of muscle, unspecified site</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Ketamine group: They receives 0.3 mg / kg / IV treatment of ketamine.</i_keyword>
      <i_keyword>Intervention group: Percedex receiving group: They receive 1 µg / kg / IV treatment of Percedex.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The primary or main outcome of this study is faster treatment of shivering in patients with shivering after anesthesia. (Reduce patients' chills). Timepoint: The degree of shivering in patients is determined and recorded before receiving the drug and from zero to 10 minutes every minute after receiving the drug. Method of measurement: Postoperative shivering grading: Based on 5-digit grading (0 to 4) Grade 0: No shivering. Grade 1: Mild cold and chills on face or neck or one or more of the symptoms: Mild peripheral vasoconstriction, peripheral cyanosis, body hair spiking for no other reason. Grade 2: Moderate chills (involvement of one muscle group: oral muscle spasm) Grade 3: Severe chills (involvement of more than one muscle group without generalized involvement: spasm of all facial muscles) Grade 4: Generalized body chills.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Body temperatures. Timepoint: Patients' body temperature is recorded 5 times before induction of anesthesia, at the time of entering the recovery, before receiving the drug, 5 minutes after receiving the drug and 10 minutes after receiving the drug. Method of measurement: It is measured from the axillary area by a thermometer.</sec_outcome>
      <sec_outcome>Hemodynamic changes. Timepoint: For both groups of patients, hemodynamic variables including HR, RR , SBP and DBP, SaO2 4 times before medication,1 minute after receiving the drug and 5 and 10 minutes after receiving the drug is recorded. Method of measurement: HR (via distal pulse of the upper limb), RR (number of patient breaths per minute), SBP and DBP (via barometer), SaO2 (via pulse oximetry).</sec_outcome>
      <sec_outcome>Side effects from medications. Timepoint: Patients are monitored and recorded for drug side effects, including nausea and vomiting, tachycardia, hypertension, nystagmus, delirium, and other side effects up to 30 minutes after receiving the drug. Method of measurement: Patients are evaluated after receiving the drug.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Sanandaj University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-01-07</approval_date>
        <contact_name>Ethics Committee of Sanandaj University of Medical Sciences</contact_name>
        <contact_address>Sanandaj University of Medical Sciences, Pasdaran Blvd., Sanandaj, Kurdistan Province Sanandaj Kurdistan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
